Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0A2UF)

Drug Name
HS-173 Drug Info
Synonyms
HS-173; 1276110-06-5; Ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate; CHEMBL1765463; HS 173; GTPL8243; SCHEMBL20768095; EX-A320; AOB6845; MolPort-035-395-894; HMS3653I16; HS173; BCP09225; BDBM50341493; ZINC71319188; s7356; 2465AH; AKOS026750419; ACN-053037; CS-6015; SB19242; NCGC00386329-02; HY-15868; BC600371; FT-0700155; SW219873-1; J3.560.887G; J-690118; ethyl 6-[5-(benzenesulfonamido)pyridin-3-yl]imidazo[1,2-a]pyridine-3-carboxylate; Ethyl 6-(5-(Phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]-pyridine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
52936849
TTD Drug ID
DM0A2UF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting PI3-kinase gamma (PIK3CG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAY 80-6946 DMLOS5R Follicular lymphoma 2A80 Approved [3]
IPI-145 DMWA24P Follicular lymphoma 2A80 Approved [4]
Buparlisib DM1WEHC Breast cancer 2C60-2C65 Phase 3 [5]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [6]
Rigosertib DMOSTXF Myelodysplastic syndrome 2A37 Phase 3 [7]
GDC-0032 DMT4QHD Breast cancer 2C60-2C65 Phase 3 [6]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [8]
SAR245409 DMQM7IL Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
XL147 DMML7BE Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
SF1126 DML10K3 Head and neck cancer 2D42 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [2]

References

1 HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis. Sci Rep. 2013 Dec 11;3:3470.
2 Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis. J Med Chem. 2011 Apr 14;54(7):2455-66.
3 BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
4 PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
5 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
10 An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.